DOCSLIB.ORG

MBDB): Its Properties and Possible Risks

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MBDB): Its Properties and Possible Risks Addiction Biology (2000) 5, 269 ± 282 INVITED REVIEW N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks L. A. G. J. M. VAN AERTS,1 M. MALLARET 2 & H. RIGTER 1Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands & 2Centre Hospitalier Universitaire de Grenoble, Laboratoire de Pharmacologie, Grenoble, France. Abstract MBD B (N -methyl-1 -(1,3-benzodioxol-5-yl)-2-aminobutane) is the a -ethyl homologue of MDMA (3,4-methylenedioxy-N-methylamphetam ine). MBDB is metabolized and excreted similarly to MDMA: presumably, the majority of oral MBDB is excreted in urine unmetabolized. The main metabolic routes in man are thought to be O-dealkylation and subsequent methylation, sulphation and glucuronidation of the newly formed hydroxy groups. The major acute neuropharmacological effects of M BDB in the rat are an increase in serotonin release in the brain and an inhibition of serotonin and noradrenaline re-uptake. These effects compare well with those of MDMA, although the latter is more potent. M BDB may also slightly increase dopamine release and inhibit dopamine re-uptake, but to a lesser extent than MDMA. This is im portant, as dopamine release has been implicated in the reinforcing qualities of substances such as cocaine and amphetamine. The neuroendocrine effects of MBD B resemble those of MDMA. Both substances increase plasma ACTH, corticosterone, prolactin and renin. The neurophysiological effects of MBD B are characterized by a decrease in electrical activity throughout the brain, most notably in the alpha2 and delta frequency bands. In contrast, hallucinogens increase the activity in the alpha1 band, especially in the corpus striatum. In drug discrimination tests in the rat, MBD B, like MDMA, can be distinguished clearly from both stimulants and hallucinogens. The class of substances to which MBDB belongs may be named entactogens. MBDB dose-dependently increases locomotor activity and decreases explorator y behaviour in the rat and causes distress vocalization and wing extension in the newly hatched chicken. The rewarding properties of MBDB appear to be smaller than those of MDMA, as suggested by a 2.5 times weaker potency in the conditioned place preference test in rats. The main Correspondence to: Dr L.A.G.J.M. van Aerts, National Institute of Public Health and Environment, Laboratory of Medicines and Medical Devices, PO Box 1, 3720 BA Bilthoven, The Netherlands. Received for publication 12th November 1998. Accepted 16th March 2000. Abbreviations BDB, 1-(1,3-benzodioxol-5-yl)-2-aminobutane; CPP, conditioned place preference; DOB, 2,5-dimethoxy- 4-bromo-amphetamine; DOI, 2,5-dimethoxy-4-iodo-amphetamine; DOM, 2,5-dimethoxy-4-methyl-ampheta- mine; DOPAC, 3,4-dihydroxyphenylacetic acid; EMCDDA, European Monitoring Centre for Drugs and Drug Addiction; MBDB, N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane; MDA, 3,4-methylenedioxyamphetamine; MDAI, 5,6-methylenedioxy-2-aminoindan; MDEA, 3,4-methylenedioxy-N-ethylamphetamine; MDMA, 3,4-methylenedioxy-N-methylamphetamine; MMAI, 5-methoxy-6-methyl-2-aminoindan; MMBDB, N,N-dime- thyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane; MTA, 4-methylthioamphetamine. Note: Unless stated otherwise, the weights and concentrations of the substances mentioned in the text are (supposedly) based on the hydrochloride salt form, although this was not always specified in the original papers. ISSN 1355-6215 print/ISSN 1369-16 00 online/00/030269 -14 Society for the Study of Addiction to Alcohol and Other Drugs Carfax Publishing, Taylor & Francis Ltd 270 L. A. G. J. M. van Aerts et al. subjective effects of MBDB in man are a pleasant state of introspection, with greatly facilitated interpersonal comm unication and a pronounced sense of empathy and compassion between subjects. In this respect, MBDB again resembles M DMA. However, there are also differences. MBDB has a slower and more gentle onset of action than MDM A, produces less euphoria and has less stimulant properties. The few toxicological data available suggest that MBDB may cause serotonergic deficits in the brain, although the potency of MBDB to cause this neurotoxic effect is smaller than that of MDMA. Severe acute reactions in man as have been reported for MDMA have not been published for MBDB. The dependence potential of MBDB appears to be small, probably even sm aller than that of MDMA. MBDB has been available at least since 1994 but its position on the synthetic drugs market is marginal. Subjective reports indicate that MBDB is less popular among users than MDMA. The reason may be that M BDB produces less euphoria than M DMA. Another possible explanation is that MBDB largely lacks the stim ulant properties of MDMA. We calculated a margin of safety with a method similar to one used in the risk assessment of pharmaceuticals. The results suggest that MBDB is three times less likely to cause serotonergic brain deficits than MDMA. However, it should be noted that for both substances the margin of safety is less than one, indicating that the risk of neurotoxicity is not negligible. In animals, serotonergic brain deficits after exposure to MDMA have been linked to the degeneration of serotonergic ner ve ter minals. Introduction d incorporate a mechanism for assessing the risks Much has been done to clarify the mechanism of of these drugs; and the pharmacological actions and toxicity of d comprise a decision-making process through 3,4-methylenedioxy-N-methylamphetamine which these products may be placed under (MDMA, ª ecstasyº ). Even though substantial control in the EU Member States. progress has been made, we still do not know exactly how MDMA works and how risky the use In addition, we present at the end of this paper a of this substance is. Compared with MDMA, method for risk assessment of health risks asso- N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobu- ciated with the use of MBDB. The purpose of this tane (MBDB) has received little attention from assessment is to illustrate how scientific knowl- the scientific community. Therefore, our under- edge can be used to evaluate the risks of non- standing of the pharmacological and toxicological medically used psychoactive drugs. actions of MBDB is much smaller, and the risks of consuming MBDB are even harder to estimate than for MDMA. In this report, the scientific Chem ical description knowledge on MBDB will be reviewed. The MDMA is short for 3,4-methylenedioxymetham - MBDB data will be compared with those for phetamine it could also be named N -methyl- MDMA, which is similar in structure and action. 1-(1,3-benzodioxol-5-yl)-2-aminopropane. The For a more thorough review of the properties and molecular structure is shown in Fig. 1. The main effects of MDMA, the reader is referred to three precursors for synthesizing of MDMA are piper- recent publications.1 ± 3 onylmethylketone, piperonal, safrole and The data on MBDB reviewed here have been isosafrole. used by the Scientific Committee of the Euro- MBDB is N-methyl-1-(1,3-benzodioxol-5-yl)- pean Monitoring Centre for Drugs and Drug 2-aminobutane (Fig. 1). It is the a -ethyl homo- Addiction (EMCDDA) for the risk assessment on logue of MDMA. The free base is a colourless oil MBDB within the framework of a Joint Action with a melting point of 88ÆC at 0.08 mm Hg. The adopted by the Council of the European Union hydrochloride salt consists of colourless crystals on 16 June 1997.1 4 This Joint Action on New with a melting point of 156ÆC.5 Nuclear magnetic Synthetic Drugs aims to: resonance data were reported by Nichols and co- workers.5 MBDB can be synthesized from d provide for the establishment of an early- 1-(1,3-benzodioxol-5-yl)-2-aminobutane (BDB). warning system to identify new synthetic drugs The extra carbon atom in this precursor com- as they appear on the European market; pared with MDMA precursors prevents MBDB Properties and possible risks of MBDB 271 Table 2. MBDB samples identified by Drug Information and Monitoring System: pharmaceutical forms Pharmaceutical form Number % Tablets 169 83 Powders/capsules 32 16 Fluids 3 1 Total 204 100 content of the tablet, but the dynamics of the Figure 1. Structural formulae of MDMA (above) and ecstasy market are such that these markings may MBDB (below). become misleading.1 0 Therefore, MBDB should be considered an integral part of the ecstasy market. from turning up by accident when one attempts to synthesize MDMA or vice versa. BDB is not commercially available. It can be synthesized Route of administration and dosage from piperonal and 1-nitropropane or 1-bromo- As a rule, MDMA is ingested. Accounts of propane. MBDB can be analysed with gas chro- intravenous administration or snorting of this matography/mass spectrometry (GC/MS). With drug are rare. Typical doses taken orally range these methods, MBDB can be distinguished from from 50 to 150 mg. Although many users take congeners such as MDMA, 3,4-methylenedioxy- single doses, multiple dosing is not uncommon. N-ethylamphetamine (MDEA) and 3,4-methyle- Many users concomitantly use other psychoactive nedioxyamphetamine (MDA).6 ± 9 substances, such as tobacco, alcohol, cannabis, amphetamine and LSD. MBDB is also taken orally. Shulgin & Shul- Pharmaceutical form gin11 and Nichols and co-workers5 reported on MDMA is mainly sold as tablets, and occasion- consumption of 150 ± 210 mg, and MBDB con- ally as capsules or powders. Tablets often show taining street samples analysed by Rothe and co- distinctive markings (logos). MDMA is traded workers9 contained, on average, 197 mg. In con- under the name ecstasy (XTC). MBDB is vir- trast, most Member States reported to the tually always sold as ª ecstasyº (Table 1). It has EMCDDA that the mean amount of MBDB the same pharmaceutical appearance as MDMA found in tablets is about 100 mg.
Load more

Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • Quantification of Drugs of Abuse in Municipal Wastewater Via SPE and Direct Injection Liquid Chromatography Mass Spectrometry
    Anal Bioanal Chem (2010) 398:2701–2712 DOI 10.1007/s00216-010-4191-9 ORIGINAL PAPER Quantification of drugs of abuse in municipal wastewater via SPE and direct injection liquid chromatography mass spectrometry Kevin J. Bisceglia & A. Lynn Roberts & Michele M. Schantz & Katrice A. Lippa Received: 2 June 2010 /Revised: 30 August 2010 /Accepted: 2 September 2010 /Published online: 24 September 2010 # US Government 2010 Abstract We present an isotopic-dilution direct injection 50 ng/L. We also present a modified version of this method reversed-phase liquid chromatography–tandem mass spec- that incorporates solid-phase extraction to further enhance trometry method for the simultaneous determination of 23 sensitivity. The method includes a confirmatory LC separa- drugs of abuse, drug metabolites, and human-use markers in tion (selected by evaluating 13 unique chromatographic municipal wastewater. The method places particular emphasis phases) that has been evaluated using National Institute of on cocaine; it includes 11 of its metabolites to facilitate Standards and Technology Standard Reference Material 1511 assessment of routes of administration and to enhance the Multi-Drugs of Abuse in Freeze-Dried Urine. Seven analytes accuracy of estimates of cocaine consumption. Four opioids (ecgonine methyl ester, ecgonine ethyl ester, anhydroecgo- (6-acetylmorphine, morphine, hydrocodone, and oxycodone) nine methyl ester, m-hydroxybenzoylecgonine, p-hydroxy- are also included, along with five phenylamine drugs benzoyl-ecgonine, ecgonine, and anhydroecgonine) were (amphetamine, methamphetamine, 3,4-methylenedioxy- detected for the first time in a wastewater sample. methamphetamine, methylbenzodioxolyl-butanamine, and 3,4-methylenedioxy-N-ethylamphetamine) and two human- Keywords Wastewater . Illicit drugs . Urinary metabolites . use markers (cotinine and creatinine).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: Lmmunocytochemical Evidence for Neurotoxicity
    The Journal of Neuroscience, August 1988, 8(8): 2788-2803 Methylenedioxyamphetamine (MDA) and Methylenedioxymetham- phetamine (MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: lmmunocytochemical Evidence for Neurotoxicity E. O’Hearn,” G. Battaglia, lab E. B. De Souza,’ M. J. Kuhar,’ and M. E. Molliver Departments of Neuroscience, and Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and ‘Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, Baltimore, Maryland 21224 The psychotropic amphetamine derivatives 3,4-methylene- The synthetic amphetamine derivatives 3,4-methylenedioxy- dioxyamphetamine (MDA) and 3,4-methylenedioxymetham- amphetamine (MDA) and 3,4-methylenedioxymethamphet- phetamine (MDMA) have been used for recreational and amine (MDMA) are potent mood-altering drugs that have at- therapeutic purposes in man. In rats, these drugs cause large tained public interest (Seymour, 1986) due to their widespread, reductions in brain levels of serotonin (5HT). This study self-administration by young adults (e.g., Klein, 1985). These employs immunocytochemistry to characterize the neuro- drugs have also been proposed for medical use in psychotherapy toxic effects of these compounds upon monoaminergic neu- because they produce augmentation of mood and enhanced in- rons in the rat brain. Two weeks after systemic administra- sight (Naranjo et al., 1967; Yensen et al., 1976; Di Leo, 198 1; tion of MDA or MDMA (20 mg/kg, s.c., twice daily for 4 d), Greer and Tolbert, 1986; Grinspoon and Bakalar, 1986). How- there is profound loss of serotonergic (5HT) axons through- ever, concern has been raised about the safety of these com- out the forebrain; catecholamine axons are completely pounds based on evidence that they may be toxic to brain seroto- spared.
    [Show full text]
  • MDMA, MBDB' and I! I the Classichallucinogens
    Differences Between the Mechanism I t of Action of MDMA, MBDB' and i! I the ClassicHallucinogens. i Identification of a New Therapeutic Class: Entactogens Jawi'ri", ! 7 U$ DAVID E. NICHOLS, PH.D.* The widespread use of psychedelic drugs, such as quantitative structure-activity relationships (QSARs). lysergic ac;.d diethylamide (LSD), during the 1960's and Simply stated, attempts are made to find quantitative 1970's IcC to severe reactions by governmental agencies correlations (or equations) that relate biological activity to and proscriptions against their use. However, with the fundamental properties of the molecule. This approach is high deg _e of interest in mind-altering drugs in the being widely developed in the pharmaceutical industry in United States, as evidenced by their widespread popular- order to understand more fully how particular types of ity, it wasonlyamatteroftimebeforenewdrugsappeared drugs work, and to be able to predict which additional that were developed outside of the pharmaceutical corn- molecules should be synthesized. It should also be added panics, that no equations have been developed that adequately j Nearly 70 years after its first synthesis, 3,4- correlate hallucinogenic or psychedelic activity with any methy'enedioxymethamphetamine (MDMA) was redis- particular molecular property. covered. Although it had its' more recent origin in the class In this context, it is important to define clearly the of dr. gs that is generally defined as psychedelic or hallu- type of biological activity that is being measured. It is cino enic, it clearly appears different from LSD. In hu- typical that if a molecule has several different sites of mar , MDMA induces a state of reduced anxiety and action in the brain, that each oneof these actions may be lc .red defensiveness that makes it attractive to thera- related to entirely different structural features or proper- pi .
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • AGENDA Friday, September 9, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
    [Show full text]
  • Aminoindanesthe Next Wave of Legal Highs?
    Drug Testing Review and Analysis Received: 23 May 2011 Accepted: 24 May 2011 Published online in Wiley Online Library: 11 July 2011 (www.drugtestinganalysis.com) DOI 10.1002/dta.318 Aminoindanes – the next wave of ‘legal highs’? P.D. Sainsbury,a A.T. Kicman,a R.P. Archer,b L.A. Kinga and R.A. Braithwaitea∗ Due to its closed ring system, 2-aminoindane is a conformationally rigid analogue of amphetamine. Internet websites offering synthetic compounds as ‘research chemicals’ have recently been advertising 5,6-methylenedioxy-2-aminoindane (MDAI), 5, 6-methylenedioxy-N-methyl-2-aminoindane (MDMAI), 5-iodo-2-aminoindane (5-IAI), and 5-methoxy-6-methyl-2-aminoindane (MMAI). The chemistry, pharmacology, and toxicological aspects of this new class of psychoactive substances are reviewed, as these could become the next wave of ‘legal highs’. Copyright c 2011 John Wiley & Sons, Ltd. Keywords: aminoindanes; legal highs; MDAI; MDMAI; 5-IAI; MMAI; serotonin. Introduction Pharmacology Although Solomons and Sam reported in 1973 that the aminoin- Historically, the terms ‘legal highs’ and ‘herbal highs’ referred to danes possessed significant bronchodilating and analgesic blends of psychoactive plants or fungi that could be smoked properties,[2] more recent research points to the aminoindanes as or ingested to induce dissociative effects and hallucinations. having potent effects on serotonin release and re-uptake. A num- These terms, however, have more recently been widened to ber of studies undertaken in the late 1980s and early 1990s con- describe an extensive and growing range of entirely synthetic cerning Ecstasy (3,4-methylenedioxymethamphetamine; MDMA) substances that have become popular as recreational drugs of also included a comparison with a number of MDMA analogues abuse; this coincides with a period of intense media interest that incorporated an indane ring.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • 4-Fluoroamphetamine (4-FA) Critical Review Report Agenda Item 4.3
    4-Fluoroamphetamine (4-FA) Critical Review Report Agenda Item 4.3 Expert Committee on Drug Dependence Thirty-ninth Meeting Geneva, 6-10 November 2017 39th ECDD (2017) Agenda item 4.3 4-FA Contents Acknowledgements.................................................................................................................................. 4 Summary...................................................................................................................................................... 5 1. Substance identification ....................................................................................................................... 6 A. International Nonproprietary Name (INN).......................................................................................................... 6 B. Chemical Abstract Service (CAS) Registry Number .......................................................................................... 6 C. Other Chemical Names ................................................................................................................................................... 6 D. Trade Names ....................................................................................................................................................................... 6 E. Street Names ....................................................................................................................................................................... 6 F. Physical Appearance ......................................................................................................................................................
    [Show full text]
  • 2021 Il Mmai
    MeridianComplete (Medicare-Medicaid Plan) 2021 List of Covered Drugs (Formulary) Formulary ID: 21425 Version Number: 21 Updated on 8/24/2021. For more recent information or other questions, contact us at 1-855-580-1689 (TTY users should call 711). Representatives are available Monday-Friday, 8 a.m. to 8 p.m. to assist you. On weekends and on state or federal holidays, you may be asked to leave a message. Your call will be returned within the next business day. Or visit corp.mhplan.com/en/member/illinois/complete/. H6080_MMP_61396E_Accepted DIR053819ET00 H6080_MMP_61396E_Approved MeridianComplete | 2021 List of Covered Drugs (Formulary) Introduction This document is called the List of Covered Drugs (also known as the Drug List). It tells you which prescription drugs and over-the-counter drugs and items are covered by MeridianComplete (Medicare-Medicaid Plan). The Drug List also tells you if there are any special rules or restrictions on any drugs covered by MeridianComplete. Key terms and their definitions appear in the last chapter of the Member Handbook. Table of Contents A. Disclaimers ............................................................................................................................... 3 B. Frequently Asked Questions (FAQ) .......................................................................................... 4 B1. What prescription drugs are on the List of Covered Drugs? (We call the List of Covered Drugs the “Drug List” for short.) ........................................................................................
    [Show full text]